Regulators approved two separate indications for fam-trastuzumab deruxtecan-n, extending use of the HER2-targeted antibody-drug conjugate into additional clinical settings. The label updates matter for patient selection strategies and potential sequencing decisions across HER2-positive and related oncologic disease states, particularly where ADC options increasingly compete for lines of therapy.